Breathing test could help doctors personalize antibody therapy for immune deficiency
NCT ID NCT05193552
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a simple breathing test (spirometry) can help doctors decide the right dose of immunoglobulin therapy for people with common variable immune deficiency (CVID). Researchers will enroll 22 adults with CVID who already take a stable dose of Hizentra. Half will stay on their current dose, while the other half will get a slightly higher dose for 6 months. The goal is to see if the higher dose improves lung function and reduces fatigue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hizentra (subcutaneous immunoglobulin)
What this could lead to
If successful, this could give doctors a simple way to fine-tune immunoglobulin doses for people with CVID, potentially improving lung health and quality of life.
What could go wrong
This is a very small early-phase study with only 22 participants, so results may not apply to everyone. It is testing a dosing strategy, not a new drug, so the impact is likely modest.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMMON VARIABLE IMMUNODEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Community Health 20
RECRUITINGBirmingham, Alabama, 35205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••